Terms: = Breast cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Treatment
1003 results:
1. In Vitro Antiviral and Anticancer Effects of Tanacetum sinaicum Essential Oil on Human Cervical and breast cancer.
Sheashea AA; Ahmed FA; El Zayat E; Ebeed BW; Elberry MH; Hassan ZKM; Hafez MM
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1457-1471. PubMed ID: 38680008
[TBL] [Abstract] [Full Text] [Related]
2. Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit.
Engström T; Ekholm M; Fernö M; Lundgren C; Nordenskjöld B; Stål O; Bendahl PO; Tutzauer J; Rydén L
Acta Oncol; 2024 Apr; 63():125-136. PubMed ID: 38587062
[TBL] [Abstract] [Full Text] [Related]
3. Challenges in Diagnosis and treatment of Male Hypogonadism.
Purnamasari D
Acta Med Indones; 2024 Jan; 56(1):1-2. PubMed ID: 38561883
[TBL] [Abstract] [Full Text] [Related]
4. Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive breast cancer with Brain Metastases.
Wang C; Xiang J; Zhang Q; Li J; Liu Y; Liu J
Drug Des Devel Ther; 2024; 18():909-917. PubMed ID: 38545432
[TBL] [Abstract] [Full Text] [Related]
5. Validation of primary and outcome data quality in a Swedish population-based breast cancer quality registry.
Palmér S; Blomqvist C; Holmqvist M; Lindman H; Lambe M; Ahlgren J
BMC Cancer; 2024 Mar; 24(1):329. PubMed ID: 38468209
[TBL] [Abstract] [Full Text] [Related]
6. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.
Piscitelli J; Reddy MB; Wollenberg L; Del Frari L; Gong J; Wood L; Zhang Y; Matschke K; Williams JH
Clin Pharmacokinet; 2024 Apr; 63(4):483-496. PubMed ID: 38424308
[TBL] [Abstract] [Full Text] [Related]
7. Feasibility of measuring comorbidity indices based on clinical breast cancer records.
Eslami B; Alipour S; Seyyedsalehi MS; Nahvijou A; Omranipour R; Rajabpour MV; Zendehdel K
East Mediterr Health J; 2023 Nov; 26(11):870-876. PubMed ID: 38279882
[TBL] [Abstract] [Full Text] [Related]
8. Exploring the Potential of Montmorillonite as an Antiproliferative Nanoagent against MDA-MB-231 and MCF-7 Human breast cancer Cells.
Sabzevari AG; Sabahi H; Nikbakht M; Azizi M; Dianat-Moghadam H; Amoozgar Z
Cells; 2024 Jan; 13(2):. PubMed ID: 38275825
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients.
Zheng X; Fang M; Fan Y; Sun Y; Sun M; Yang A; Zhang B; Liu Q; Liu H; Zhou X; Huang T; Qin J; Wang Z; Qin M; Shen Z; Yao S; Yang J; Wang Y; Gao M
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38261313
[TBL] [Abstract] [Full Text] [Related]
10. Hindering the unlimited proliferation of tumor cells synergizes with destroying tumor blood vessels for effective cancer treatment.
Liu Y; Xu Y; Wang Y; Lv J; Wang K; Tang Z
Biomater Sci; 2024 Feb; 12(5):1294-1306. PubMed ID: 38258411
[TBL] [Abstract] [Full Text] [Related]
11. [Guideline for the management path and quality control of breast cancer prevention and treatment in China's counties (2023 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2024 Jan; 46(1):1-18. PubMed ID: 38246777
[TBL] [Abstract] [Full Text] [Related]
12. Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced breast cancer.
Ji Y; Schiller H; Yang S; Quinlan M; Darstein C; Huth F; Winter S; Chakraborty A
Clin Pharmacokinet; 2024 Feb; 63(2):155-170. PubMed ID: 38244190
[TBL] [Abstract] [Full Text] [Related]
13. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Fan L; Wang ZH; Ma LX; Wu SY; Wu J; Yu KD; Sui XY; Xu Y; Liu XY; Chen L; Zhang WJ; Jin X; Xiao Q; Shui RH; Xiao Y; Wang H; Yang YS; Huang XY; Cao AY; Li JJ; Di GH; Liu GY; Yang WT; Hu X; Xia Y; Liang QN; Jiang YZ; Shao ZM
Lancet Oncol; 2024 Feb; 25(2):184-197. PubMed ID: 38211606
[TBL] [Abstract] [Full Text] [Related]
14. Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced breast cancer and Brain Metastases: A Nonrandomized Phase 2 Trial.
Yang Z; Meng J; Mei X; Mo M; Xiao Q; Han X; Zhang L; Shi W; Chen X; Ma J; Palmer J; Shao Z; Zhang Z; Yu X; Guo X
JAMA Oncol; 2024 Mar; 10(3):335-341. PubMed ID: 38175627
[TBL] [Abstract] [Full Text] [Related]
15. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Lin CC; Garralda E; Schöffski P; Hong DS; Siu LL; Martin M; Maur M; Hui R; Soo RA; Chiu J; Zhang T; Ma B; Kyi C; Tan DS; Cassier PA; Sarantopoulos J; Weickhardt A; Carvajal RD; Spratlin J; Esaki T; Rolland F; Akerley W; Deschler-Baier B; Rispoli L; Samant TS; Chowdhury NR; Gusenleitner D; Kwak EL; Askoxylakis V; De Braud F
Oncoimmunology; 2024; 13(1):2290787. PubMed ID: 38170160
[TBL] [Abstract] [Full Text] [Related]
16. Low-dose daily folic acid (400 μg) supplementation does not affect regulation of folate transporters found present throughout the terminal ileum and colon of humans: a randomized clinical trial.
Farrell CC; Khanna S; Hoque MT; Plaga A; Basset N; Syed I; Biouss G; Aufreiter S; Marcon N; Bendayan R; Kim YI; O'Connor DL
Am J Clin Nutr; 2024 Mar; 119(3):809-820. PubMed ID: 38157986
[TBL] [Abstract] [Full Text] [Related]
17. Germline testing of
Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
[TBL] [Abstract] [Full Text] [Related]
18. Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer.
Kim K; Kim H; Shin I; Noh SJ; Kim JY; Suh KJ; Kim YN; Lee JY; Cho DY; Kim SH; Kim JH; Lee SH; Choi JK
Sci Rep; 2023 Dec; 13(1):22482. PubMed ID: 38110532
[TBL] [Abstract] [Full Text] [Related]
19. Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative breast cancer.
Zhang C; Zhu J; Yuan X; Yan Z; Ye H; Xiong T; Xu A; Li C; Ji D; Yang S; Zhang J; Zhang Y; Wu J; Huang Z
J Med Chem; 2024 Jan; 67(1):479-491. PubMed ID: 38110353
[TBL] [Abstract] [Full Text] [Related]
20. Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial.
Zheng Y; Cao WM; Shao X; Shi Y; Cai L; Chen W; Liu J; Shen P; Chen Y; Wang X; Li H; Li M; Chen Z; Wang X
Nat Commun; 2023 Dec; 14(1):8314. PubMed ID: 38097605
[TBL] [Abstract] [Full Text] [Related]
[Next]
